| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
41,610,000 |
| Market
Cap: |
83.22(M) |
| Last
Volume: |
1,136,985 |
Avg
Vol: |
1,133,856 |
| 52
Week Range: |
$0.900001 - $2.955 |
|
| Level
I Sector: |
Consumer Discretionary |
| Level
II Sector: |
Media |
| Level
III Sector: |
Broadcasting - TV |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Brooklyn ImmunoTherapeutics is a clinical-stage biopharmaceutical company focused on exploring the role that cytokine-based therapy can have on the immune system in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Co. is seeking to develop IRX-2, a cytokine-based therapy, to treat patients with cancer. Co. also is exploring opportunities to advance oncology, blood disorder, and monogenic disease therapies using gene-editing and cell therapy technology through a license with Factor Bioscience Limited and through its subsidairies, Novellus, Inc. and Novellus, Ltd.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
880,962 |
| Total Buy Value |
$0 |
$0 |
$0 |
$2,889,556 |
| Total People Bought |
0 |
0 |
0 |
3 |
| Total Buy Transactions |
0 |
0 |
0 |
3 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Wolff Allen |
CEO |
• – – |
2020-01-19 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
131,701 |
|
- |
|
| Simtob Richard Isaac |
Director |
– • – |
2019-12-31 |
4 |
A |
$0.00 |
$0 |
D/D |
3,851 |
55,939 |
|
- |
|
| Berg Jeffrey Alan |
10% Owner |
– – • |
2019-12-23 |
4 |
S |
$2.45 |
$490 |
I/I |
(200) |
421,100 |
|
- |
|
| Ellin Robert S |
10% Owner |
– – • |
2019-12-20 |
4 |
B |
$2.83 |
$850 |
I/I |
300 |
199,494 |
1.42 |
- |
|
| Ellin Robert S |
10% Owner |
– – • |
2019-12-20 |
4 |
B |
$2.77 |
$277 |
D/D |
100 |
157,171 |
2.37 |
- |
|
| Berg Jeffrey Alan |
10% Owner |
– – • |
2019-12-20 |
4 |
S |
$2.72 |
$4,624 |
I/I |
(1,700) |
421,300 |
|
- |
|
| Wolff Allen |
Interim CEO |
• – – |
2019-12-19 |
4 |
D |
$2.73 |
$661 |
D/D |
(242) |
56,701 |
|
- |
|
| Gurrola Sandra M |
SVP of Finance |
• – – |
2019-12-19 |
4 |
D |
$2.73 |
$257 |
D/D |
(94) |
9,038 |
|
- |
|
| Ellin Robert S |
10% Owner |
– – • |
2019-12-19 |
4 |
B |
$2.72 |
$814 |
I/I |
299 |
199,294 |
1.42 |
- |
|
| Ellin Robert S |
10% Owner |
– – • |
2019-12-05 |
4 |
B |
$2.90 |
$290 |
D/D |
100 |
157,071 |
2.37 |
- |
|
| Wolff Allen |
Interim CEO |
• – – |
2019-11-20 |
4 |
D |
$2.62 |
$631 |
D/D |
(241) |
56,943 |
|
- |
|
| Gurrola Sandra M |
SVP of Finance |
• – – |
2019-11-20 |
4 |
D |
$2.62 |
$249 |
D/D |
(95) |
9,132 |
|
- |
|
| Ellin Robert S |
10% Owner |
– – • |
2019-10-29 |
4 |
B |
$3.15 |
$2,776 |
I/I |
881 |
198,895 |
1.42 |
- |
|
| Ellin Robert S |
10% Owner |
– – • |
2019-10-25 |
4 |
B |
$3.21 |
$321 |
I/I |
100 |
198,014 |
1.42 |
- |
|
| Ellin Robert S |
10% Owner |
– – • |
2019-10-24 |
4 |
B |
$3.03 |
$613 |
D/D |
202 |
156,971 |
2.37 |
- |
|
| Ellin Robert S |
10% Owner |
– – • |
2019-10-23 |
4 |
B |
$2.70 |
$6,192 |
I/I |
2,295 |
197,914 |
1.5 |
- |
|
| Ellin Robert S |
10% Owner |
– – • |
2019-10-23 |
4 |
B |
$2.85 |
$7,140 |
D/D |
2,506 |
156,769 |
2.37 |
- |
|
| Wolff Allen |
Interim CEO |
• – – |
2019-10-23 |
4 |
D |
$2.88 |
$694 |
D/D |
(241) |
57,184 |
|
- |
|
| Gurrola Sandra M |
SVP of Finance |
• – – |
2019-10-23 |
4 |
D |
$2.88 |
$271 |
D/D |
(94) |
9,277 |
|
- |
|
| Ellin Robert S |
10% Owner |
– – • |
2019-10-14 |
4 |
B |
$3.50 |
$350 |
I/I |
100 |
198,995 |
1.42 |
- |
|
| Ellin Robert S |
10% Owner |
– – • |
2019-10-14 |
4 |
B |
$3.66 |
$1,097 |
D/D |
300 |
154,263 |
2.37 |
- |
|
| Ellin Robert S |
10% Owner |
– – • |
2019-10-08 |
4 |
B |
$3.67 |
$367 |
I/I |
100 |
195,619 |
1.42 |
- |
|
| Ellin Robert S |
10% Owner |
– – • |
2019-10-04 |
4 |
B |
$2.90 |
$372 |
I/I |
128 |
195,519 |
1.42 |
- |
|
| Ellin Robert S |
10% Owner |
– – • |
2019-10-03 |
4 |
B |
$3.12 |
$827 |
I/I |
265 |
195,391 |
1.42 |
- |
|
| Ellin Robert S |
10% Owner |
– – • |
2019-10-01 |
4 |
B |
$3.43 |
$718 |
I/I |
200 |
195,126 |
1.42 |
- |
|
406 Records found
|
|
Page 4 of 17 |
|
|
0.03 (1.48%) 
